HC Wainwright & Co. Maintains Buy on Ikena Oncology, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado maintains a 'Buy' rating on Ikena Oncology (NASDAQ:IKNA), but has lowered the price target from $18 to $11.
November 09, 2023 | 10:53 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ikena Oncology's price target has been lowered from $18 to $11 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Ikena Oncology by HC Wainwright & Co. indicates a potential decrease in the stock's value in the short term. However, the maintenance of the 'Buy' rating suggests that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100